"Item Id","Item URI","Dublin Core:Title","Dublin Core:Subject","Dublin Core:Description","Dublin Core:Creator","Dublin Core:Source","Dublin Core:Publisher","Dublin Core:Date","Dublin Core:Contributor","Dublin Core:Rights","Dublin Core:Relation","Dublin Core:Format","Dublin Core:Language","Dublin Core:Type","Dublin Core:Identifier","Dublin Core:Coverage","Item Type Metadata:Bibliography","Item Type Metadata:Biographical Text","Item Type Metadata:Occupation","Item Type Metadata:Death Date","Item Type Metadata:Birthplace","Item Type Metadata:Text","Item Type Metadata:Player","Item Type Metadata:Access","Item Type Metadata:Alternate URL","Item Type Metadata:Citation","Item Type Metadata:Accessibility","Item Type Metadata:Abstract","Item Type Metadata:Read Online","Item Type Metadata:Additional Exercise","Item Type Metadata:Email Body","Item Type Metadata:Interviewer","Item Type Metadata:Interviewee","Item Type Metadata:Location","Item Type Metadata:Transcription","Item Type Metadata:Local URL","Item Type Metadata:Original Format","Item Type Metadata:Physical Dimensions","Item Type Metadata:Duration","Item Type Metadata:Compression","Item Type Metadata:Producer","Item Type Metadata:Director","Item Type Metadata:Bit Rate/Frequency","Item Type Metadata:Time Summary","Item Type Metadata:Birth Date","Item Type Metadata:Subject Line","Item Type Metadata:From","Item Type Metadata:To","Item Type Metadata:CC","Item Type Metadata:BCC","Item Type Metadata:Number of Attachments","Item Type Metadata:Standards","Item Type Metadata:Objectives","Item Type Metadata:Materials","Item Type Metadata:Lesson Plan Text","Item Type Metadata:URL","Item Type Metadata:Event Type","Item Type Metadata:Participants","PDF Text:Text",tags,file,itemType,collection,public,featured 381,https://repository.netecweb.org/items/show/381,"Treatment outcome, survival and their risk factors among new tuberculosis patients co-infected with HIV during the Ebola outbreak in Conakry/L’issue du traitement, la survie et ses facteurs de risque chez les nouveaux tuberculeux co-infectés par le VIH pendant l’épidémie d’Ebola à Conakry","Contenu Français","Mortality among TB/HIV co-infected patients remains high in Africa. The study aimed to estimate survival and associated factors in a cohort of TB/HIV co-infected patients who started tuberculosis treatment during the Ebola outbreak in Conakry, Guinea.","Camara A, Sow MS, Touré A, Diallo OH, Kaba I, Bah B, Diallo TH, Diallo MS, Guilavogui T, Sow OY.",,,2017-11-01,,,,,,Publication,,,,,,,,,,,,"A. Camara, M. S. Sow, A. Toure, O. H. Diallo, I. Kaba, B. Bah, T. H. Diallo, et al. ""[Treatment Outcome, Survival and Their Risk Factors among New Tuberculosis Patients Co-Infected with Hiv During the Ebola Outbreak in Conakry]."" Rev Epidemiol Sante Publique 65, no. 6 (Nov 2017): 419-26.","pay online, or with Elsevier subscription","
La mortalité chez les patients tuberculeux co-infectés par le virus de l’immunodéficience humaine (VIH) est encore élevée en Afrique. Cette étude visait à estimer la survie et ses facteurs de risque dans une cohorte de patients tuberculeux co-infectés par le VIH qui a commencé un traitement antituberculeux durant l’épidémie d’Ebola à Conakry, en Guinée.
Une étude de cohorte prospective a été menée entre avril 2014 et décembre 2015, chez les nouveaux tuberculeux co-infectés par le VIH durant le traitement antituberculeux dans le CHU de Conakry. Les données de survie ont été analysées avec le logiciel SPSS 21.0. La méthode de Kaplan–Meier, le test du log-rank et le modèle de Cox ont été utilisés pour analyser les facteurs de risque du décès.
Sur les 573 tuberculeux co-infectés par le VIH étudiés, 86 (15,0 %) étaient décédés avant la fin du traitement antituberculeux avec 52 % des décès survenus dans les huit semaines suivant le début de traitement. La survie à 4, 12 et 24 semaines après le début du traitement de la tuberculose était de 92 %, 86 % et 83 % respectivement. Les facteurs indépendamment associés au décès chez les patients tuberculeux co-infectés par le VIH étaient, le taux de cellule CD4 < 200 cellules/mm3 (ratio du risque ajusté [RRA] : 2,25 ; IC95 % 1,16 à 4,37), avoir plus d’une infection opportuniste en plus de la tuberculose (RRA : 2,89 ; IC95 % 1,39 à 6,02) et avoir des comorbidités (RRA : 4,12 ; IC95 % 2,10 à 8,10). Une augmentation d’une unité du taux d’hémoglobine (RRA : 0,81 ; IC95 % 0,75 à 0,91) préservait du décès.
Les patients tuberculeux co-infectés par le VIH avaient un taux de létalité élevé pendant le traitement de la tuberculose. La prévention des infections opportunistes, de l’anémie et la prise en charge adéquate des comorbidités en début de traitement antituberculeux peuvent améliorer la survie de ces patients tuberculeux co-infectés par le VIH en rétablissant la fonction immunitaire.
Mortality among TB/HIV co-infected patients remains high in Africa. The study aimed to estimate survival and associated factors in a cohort of TB/HIV co-infected patients who started tuberculosis treatment during the Ebola outbreak in Conakry, Guinea.
A prospective cohort study was conducted from April 2014 to December 2015. TB patients with HIV co-infection were enrolled at the University Hospital of Conakry. Survival and risk factors were analyzed according to Kaplan–Meier's method, log-rank test and Cox's regression.
Data from 573 patients were analyzed. From these, 86 (15.0%) died before the end of treatment, 52% occurring within eight weeks of treatment onset. Survival at 4, 12 and 24 weeks after the beginning of the TB treatment was 92%, 86% and 83%, respectively. Independent risk factors associated with death were in the cell CD4 < 200 cells/mm3 [adjusted hazard ratio (AHR): 2.25; 95% CI (confidence intervals): 1.16–4.37], opportunistic infections other than TB [AHR: 2.89; 95% CI: 1.39–6.02], and comorbidities [AHR: 4.12; 95% CI: 2.10–8.10]. An increase of one unit in hemoglobin [AHR: 0.81; 95% CI: 0.75–0.91] was protective of death.
TB/HIV co-infected patients had a higher fatality rate during treatment of tuberculosis. Prevention of opportunistic infections, anemia and proper management of tuberculosis treatment in early comorbidities may improve survival for TB/HIV co-infected patients in restoring immune function.
The COVID-19 pandemic has changed the way we practice medicine and lead our lives. In addition to pulmonary symptoms; COVID-19 as a syndrome has multisystemic involvement including frequent gastrointestinal symptoms such as diarrhea. Due to microbiome alterations with COVID-19 and frequent antibiotic exposure, COVID-19 can be complicated by Clostridioides difficile infection. Co-infection with these two can be associated with a high risk of complications. Infection control measures in hospitals is enhanced due to the COVID-19 pandemic which in turn appears to reduce the incidence of hospital-acquired infections such as C. difficile infection. Another implication of COVID-19 and its potential transmissibility by stool is microbiome-based therapies. Potential stool donors should be screened COVID-19 symptoms and be tested for COVID-19.
Keywords: COVID-19; Clostridioides difficile; colitis; diarrhea; infection; pandemic.
",https://www.futuremedicine.com/doi/full/10.2217/fmb-2020-0275,,,,,,,,,,,,,,,,,,,,,,,,,,,https://pubmed.ncbi.nlm.nih.gov/33847139/,,,,"2019-nCoV,C-diff toxin,C. difficile toxin,Co-infection,Complications,Coronavirus,COVID-19,R-Res&Pub",,Publication,Discover,1,0 1727,https://repository.netecweb.org/items/show/1727,"NETEC Webinar Series (11/09/22)/Online Course: Influenza: 2022 Seasonal Update","Emergency Management","This NETEC webinar will discuss the current landscape of influenza in the United States and the predictions for this year’s flu season. Additional topics will include available therapeutics to treat common symptoms and co-infections and infection prevention and control measures for the detection, isolation, and management of influenza patients this season.